

NOTICES

Notice No. 20240222-30 Notice Date 22 Feb 2024  
Category Company related Segment Equity  
Subject Rights Entitlements of DIPNA PHARMACHEM LIMITED

Content

Trading Members of the Exchange are hereby informed that dealings in the Rights Entitlements (REs) for Renunciation of DIPNA PHARMACHEM LIMITED are permitted on the Exchange with effect from Monday, February 26, 2024. The details of Rights Entitlements (REs) are as under:

Name of the Company	DIPNA PHARMACHEM LIMITED
Type of Security	Rights Entitlements (REs)
Trading period for Renunciation of Rights Entitlements (REs)	Monday, February 26, 2024 to Monday, March 04, 2024
Scrip Code	750832
Scrip ID	DPL-RE
ISIN No.	INEQMC420013
Market Lot	250
Group	R

Please note that the Rights Issue will open on February 26, 2024 to March 07, 2024

Trading Members are further requested to note that Rights Entitlements (REs) for Renunciation shall be settled on T+1 Rolling Settlement basis. The trades shall be settled on trade-for-trade basis. The Rights Entitlements shall be tradable in dematerialized form only. Trading members shall inform all its clients about the commencement of trading in REs mentioning the ISIN of the RE and that the same shall not be mistaken for ordinary shares of the concerned company. Trading members shall include a disclaimer prominently in the contract notes / bill containing purchase of REs informing the Clients that the purchase of REs only gives them the right to participate in the ongoing Rights Issue of the concerned company by making an application with requisite application money or renounce the REs before the issue closes. REs which are neither subscribed by making an application with requisite application money nor renounced, on or before the issue Closing Date shall lapse and shall be extinguished after the issue Closing Date.

Trading Members are requested to refer the notice no- 20200305-21 dated March 05, 2020 and notice no-20200518-34 dated May 18, 2020 for further details.

Mangesh Tayde  
Deputy General Manager